<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120718</url>
  </required_header>
  <id_info>
    <org_study_id>2002-P-000890</org_study_id>
    <nct_id>NCT00120718</nct_id>
  </id_info>
  <brief_title>The Effect of Fasudil on Vascular Function in Humans</brief_title>
  <official_title>The Effect of Fasudil on Vascular Function in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects
      vascular function in patients with atherosclerosis and hyperlipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular reactivity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rho kinase expression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rho kinase activity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eNOS expression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eNOS activity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory markers</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fasudil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary artery disease

          -  Hyperlipidemia -OR-

          -  Healthy adults

        Exclusion Criteria:

          -  Unstable angina, myocardial infarction or revascularization within 3 months

          -  Symptomatic heart failure

          -  Creatinine &gt; 3.0 mg/dl

          -  Liver enzymes &gt; 3X upper limit of normal

          -  Chronic hypoxia

          -  Significant anemia

          -  Chronic inflammatory disease

          -  Pregnancy

          -  Willing to withdraw statins for duration of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Creager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2005</study_first_submitted>
  <study_first_submitted_qc>July 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2005</study_first_posted>
  <last_update_submitted>September 26, 2008</last_update_submitted>
  <last_update_submitted_qc>September 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mark A. Creager, MD</name_title>
    <organization>Brigham and Women's Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasudil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

